Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake

Movement Disorders

Volumn 15, Issue 4, 2000, Pages 692-698

  Benamer, Hani T S ^a,b   Patterson, Jim ^a   Wyper, David J ^a   Hadley, Donald M ^a   Macphee, G J A ^a   Grosset, Donald G ^a  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

123I FP CIT; Parkinson's disease; Severity; SPECT; UPDRS

Indexed keywords

DOPAMINE TRANSPORTER; N(G)FLUOROPROPYL 3BETA(4 IODOPHENYL)2BETA TROPANECARBOXYLIC ACID METHYL ESTER I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARM; ARTICLE; BRADYKINESIA; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FINGER; HAND MOVEMENT; HUMAN; LEG; MALE; MEDICAL ASSESSMENT; MUSCLE RIGIDITY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STAGING; TREMOR;

AGED; BRAIN MAPPING; CARRIER PROTEINS; CORPUS STRIATUM; DOMINANCE, CEREBRAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NORTROPANES; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0033910602     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V     Document Type: Article

References (38)

1. Hoehn M, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse 1991;9:43-49.
3. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus. J Neurochem 1991;56:192-198.
4. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93.
5. Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997;12:629-633.
6. 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988;77:192-201.
7. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
8. 11C-WIN25,428 reveals marked decline in mild Parkinson's disease. Ann Neurol 1993;34: 423-431.
9. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
10. 123I]β-CIT striatal uptake correlated with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
11. 123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Transm Suppl 1997;50:9-24.
12. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
13. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27: 183-190.
14. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
15. 123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
16. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998;25:24-30.
17. Booij J, Habraken JBA, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-1884.
18. 125I]beta-CIT-EF and [125] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol 1997;24:629-634.
19. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
20. Fahn S, Elton R, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-164.
21. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990;336:32-34.
22. Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict dopaminergic response in untreated Parkinson's disease. Neurology 1991;41:1723-1725.
23. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992;49: 1131-1134.
24. 123I]FPCIT SPECT. J Nucl Med 1999;40:753-761.
25. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996;37:1129-1133.
26. Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain. 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Stuttgart: Georg Thieme Verlag, 1988.
27. Collins L, Holmes C, Peters TM, Evans C. Automatic 3D model-based neuroanatomical segmentation. Human Brain Mapping 1995;3:190-208.
28. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 1995;2:89-101.
29. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119:585-591.
30. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane SPECT in healthy controls and early stage, drug-naive Parkinson's disease. J Nucl Med 1998;37:1143-1148.
31. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-β CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-1765.
32. Quinn N. Parkinsonism - recognition and differential diagnosis. BMJ 1995;310:447-452.
33. 123I] β-CIT: pharmacological characterisation of brain uptake in nonhuman primates. Synapes 1993;13:295-309.
34. 123I]-β-CIT. Mov Disord 1999;14:436-442.
35. Ahlskog JE, Uitti RJ, O'Connor MK, et al. Effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.
36. Carson RE, Channing MA, Blasberg RG, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993;13:24-42.
37. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FP-CIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39: 1500-1508.
38. Booij J, Winogrodzka A, Bergmans P, Wolters E Ch, Stoof JC. Monitoring the progression of dopaminergic degeneration in Parkinson's disease by 123I-β-CIT and 123-I-FP-CIT SPECT [Abstract]. Eur J Nucl Med 1999;26:1011.